BigHat Biosciences
1900 Alameda de las Pulgas
Suite 300
San Mateo
CA
94403
United States
Website: https://www.bighatbio.com/
9 articles about BigHat Biosciences
-
To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now. -
BigHat Biosciences will team up with Merck to design candidates for three drug discovery programs backed by the company’s proprietary AI technology platform. -
BigHat Biosciences Announces Research Collaboration with Merck
11/29/2022
BigHat Biosciences, Inc. today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs.
-
BigHat Biosciences Raises $75 Million in Series B Funding to Design Safer, More Effective Antibodies
7/20/2022
BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round.
-
BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors
5/11/2022
BigHat Biosciences , a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat’s board of directors.
-
BigHat Biosciences Completes Its Acquisition of Frugi Biotechnology
3/28/2022
BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology.
-
BigHat Biosciences Completes First Stage of Research Collaboration with Amgen
1/11/2022
BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody.
-
BigHat Biosciences Raises $19 Million in Series A Funding to Advance Antibody Design and Development for Safer, More Effective Treatments
2/10/2021
BigHat Biosciences, a novel protein therapeutics company and developer of an AI-guided antibody design platform, today announced it has raised $19 million in an oversubscribed Series A funding round, led by Andreessen Horowitz, with participation from prior investors 8VC, AME Cloud Ventures and Innovation Endeavors
-
BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.